Pablo García-Pavía

Aug 15, 2024 | onlinelibrary.wiley.com | Pablo García-Pavía |Neal Lakdawala |Gianfranco Sinagra |Tomás Ripoll-Vera

Introduction Variants in the LMNA gene, which encodes the lamin A and C proteins, are the cause of several clinical syndromes including dilated cardiomyopathy (DCM).1 The pathogenesis of LMNA-related DCM is unclear, but preclinical studies have suggested that several processes are altered in cardiomyocytes, including activation of pro-inflammatory, apoptotic, fibrotic and mitogen-activated protein kinase pathways.2-4 LMNA-related DCM is a progressive and malignant disease characterized by...

Dec 28, 2023 | jamanetwork.com | Sanjiv Shah |Pablo García-Pavía |Allan Klein

Key PointsQuestion  Does tafamidis, 80 mg, affect cardiac function in patients with transthyretin amyloid cardiomyopathy?

Sep 28, 2023 | onlinelibrary.wiley.com | Perry M. Elliott |Balarama Gundapaneni |Pablo García-Pavía

LETTER TO THE EDITOR Reply to ‘Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark’ Perry Elliott,  Corresponding Author Perry Elliott University College London, London, UK Corresponding author.

May 20, 2023 | nejm.org | Pablo García-Pavía |Olivier Lairez |Michele Mercuri |Robert Frost

AbstractBackgroundTransthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that depletes ATTR from the heart for the amelioration of cardiac dysfunction. NI006 is a recombinant human anti-ATTR antibody that was developed for the removal of ATTR by phagocytic immune cells.